Рекомбинантные полипептиды для терапии глазных заболеваний, сопровождающихся патологическим ангиогенезом
Диссертация
Не до конца изучены также последствия полного ингибирования всех изоформ УЕОБ, которое необходимо для достижения максимального эффекта от препаратов-блокаторов УЕОБ. Находится всё больше подтверждений тому, что УЕвЕ необходим для выживания фоторецепторных и Мюллеровских клеток, и системная нейтрализация этого ростового фактора может приводить к снижению функций сетчатки. Созданные нами… Читать ещё >
Список литературы
- Folkman J., Ingber D. Inhibition of angiogenesis // Semin. Cancer Biol. 1992. V. 3.
- Cao Y. Endogenous angiogenesis inhibitors and their therapeutic implications // Int. J. Biochem. Cell. Biol. 2001. V. 33. № 4. P. 357−369.
- Gao G., Ma J. Tipping the balance for angiogenic disorders // Drug Discov. Today. 2002. V. 7. № 3. P. 171−172.
- Battegay E.J. Angiogenesis: mechanistic insights, neovascular diseases, and therapeutic prospects // J. Mol. Med. 1995. V. 73. № 7. P. 333−346.
- Ma J.X., Zhang S.X., Wang J.J. Down-regulation of angiogenic inhibitors: a potential pathogenic mechanism for diabetic complications // Curr. Diab. Rev. 2005. V. 1, № 2. P. 183−196.
- Zhang S.X., Ma J.X. Ocular neovascularization: Implication of endogenous angiogenic inhibitors and potential therapy // Prog. Retin. Eye Res. 2007. V. 26. № l.P. 1−37.
- Folkman J, Shing Y. Angiogenesis // J. Biol. Chem. 1992. V. 267 № 16. P. 10 931−10 934.
- Ferrara N., Houck K., Jakeman L., Leung D.W. Molecular and biological properties of the vascular endothelial growth factor family of proteins // Endocr. Rev. 1992. V. 13. № 1. P. 18−32.
- Dawson D.W., Volpert O.V., Gillis P., Crawford S.E., Xu H., Benedict W., Bouck N.P. Pigment epithelium-derived factor: a potent inhibitor of angiogenesis // Science. 1999. V. 285. № 5425. P. 245−248
- Tolsma S.S., Volpert O.V., Good D.J., Frazier W.A., Polverini P.J., Bouck N. Peptides derived from two separate domains of the matrix protein thrombospondin- 1 have anti-angiogenic activity// J. Cell. Biol. 1993. V. 122. № 2. P. 497−511.
- Sund M., Nyberg P., Eikesdal H.P. Endogenous Matrix-Derived Inhibitors of Angiogenesis // Pharmaceuticals. 2010. V. 3. № 10. P. 3021−3039.
- Carmeliet P., Jain R.K. Molecular mechanisms and clinical applications of angiogenesis // Nature. 2011 V. 473. № 7347. P. 298−307.
- Senger D.R., Galli S.J., Dvorak A.M., Perruzzi C.A., Harvey V.S., Dvorak H.F. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid // Science. 1983. V. 219. № 4587. P. 983−985.
- Robinson C.J., Stringer S.E. The splice variants of vascular endothelial growth factor (VEGF) and their receptors // J. Cell. Sci. 2001. V. 114. P. 853−865.
- Aiello L.P., Wong J.S. Role of vascular endothelial growth factor in diabetic vascular complications // Kidney Int. Suppl. 2000. V.77. SI 13—SI 19.
- Aiello L.P., Northrup J.M., Keyt B.A., Takagi H., Iwamoto M.A. Hypoxic regulation of vascular endothelial growth factor in retinal cells // Arch. Ophthalmol. 1995. V. 113. № 12. P. 1538−44.
- Famiglietti E.V., Stopa E.G., McGookin E.D., Song P., LeBlanc V., Streeten B.W. Immunocytochemical localization of vascular endothelial growth factor in neurons and glial cells of human retina // Brain Res. 2003. V. 969. № 1−2. P. 195−204.
- Kvanta A., Algvere P.V., Berglin L., Seregard S. Subfoveal fibrovascular membranes in age-related macular degeneration express vascularendothelial growth factor // Invest. Ophthalmol. Vis. Sci. 1996. V. 37. № 9. P. 1929−1934.
- Mulcahy M.F., Benson A.B. Bevacizumab in the treatment of colorectal cancer // Expert Opin. Biol. Ther. 2005. V. 5. № 7. P. 997−1005.
- Avery L., Pieramici J., Rabena D., Castellarin A.A., Nasir M.A., Giust M.J. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration // Ophthalmology. 2006. V. 113. № 3. P. 363−372
- Bashshur Z.F., Haddad Z.A., Schakal A., Jaafar R.F., Saab M., Noureddin B.N. Intravitreal bevacizumab for treatment of neovascular age-related macular degeneration: a one-year prospective study // Am. J. Ophthalmol. 2008. V. 145. № 2. P. 249−256.
- Kriechbaum K., Michels S., Prager F., Georgopoulos M., Funk M., Geitzenauer W., Schmidt-Erfurth U. Intravitreal Avastin for macular oedema secondary to retinal vein occlusion: a prospective study // Br. J. Ophthalmol. 2008. V. 92. № 4. P. 518−522.
- Byeon S.H., Kwon Y.A., Oh H.S., Kim M, Kwon O.W. Short-term results of intravitreal bevacizumab for macular edema with retinal vein obstruction and diabetic macular edema // J. Ocul. Pharmacol. Ther. 2007. V. 23. № 4. P. 387 394.
- European Public Assessment Report (EPAR) on Avastin, European Medicine Agency (EMEA), 2005.
- Kim K.J., Li B., Houck K., Winer J., Ferrara N. The vascular endothelial growth factor proteins: identification of biologically relevant regions by neutralizing monoclonal antibodies // Growth Factors. 1992. V. 7. № 1. P. 53−64.
- Kabat E.A., Wu T.T., Perry. H.M., Gottesmann. K.S., Foeller. C. Sequences of proteins of immunological interest. Ed. 5. Public Health Service. National Institutes of Health. Bethesda. MD, 1991.
- Ferrara N., Damico L., Shams N., Lowman H., Kim R. Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration // Retina. 2006. V. 26. № 8. P. 859−870.
- Bainbridge J., Mistry A., Alwis M.D., Paleolog E., Baker A., Thrasher A.J., Ali R.R. Inhibition of retinal neovascularization by gene transfer of soluble VEGF receptor sFlt-1 // Gene Ther. 2002. V. 9. № 5. P. 320−326.
- Lai Y.K., Shen W.Y., Brankov M., Lai C.M., Constable I.J., Rakoczy P.E. Potential long-term inhibition of ocular neovascularization by recombinant adeno-associated virus-mediated secretion gene therapy // Gene Ther. 2002. V. 9. № 12. P. 804−813.
- Ferrara N., Chen H., Davis-Smyth T., Gerber H. P., Nguyen T. N., Peers D., Chisholm V., Hillan K.J., Schwall R.H. Vascular endothelial growth factor is essential for corpus luteum angiogenesis // Nat. Med. 1998. V. 4. № 3. P. 336−340.
- Gerber H.P., Vu T.H., Ryan A.M., Kowalski J., Werb Z., Ferrara N. VEGF couples hypertrophic cartilage remodeling, ossification and angiogenesis during endochondral bone formation // Nat. Med. 1999. V. 5. № 6. P. 623−628.
- Gragoudas E.S., Adamis A.P., Cunningham E.T. Jr, Feinsod M., Guyer D.R. Pegaptanib for neovascular age-related macular degeneration // N. Engl. J. Med. 2004. V. 351. № 27. P. 2805−2816.
- Eaton B. The joys of in vitro selection: chemically dressing oligonucleotides to satiate protein targets // Curr. Opin. Chem. Biol. 2005. V. 1. № l.P. 10−16.
- Pieken W.A., Olsen D.B., Benseier F., Aurup H., Eckstein F. Kinetic characterization of ribonucleaseresistant 2'-modified hammerhead ribozymes // Science. 1991. V.253. № 5017. P. 314−317.
- Healy J.M., Lewis S.D., Kurz M., Boomer R.M., Thompson K.M., Wilson C., McCauley T.G. Pharmacokinetics and biodistribution of novel aptamer compositions // Pharm. Res. 2004. V. 21. № 12. 2234−2246.
- Fairbrother W.J., Champe M.A., Christinger, H.W., Keyt, B.A., Starovasnik M.A. Solution structure of the heparin-binding domain of vascular endothelial growth factor // Structure. 1998. V. 6. № 5. P. 637−648.
- Ng E.W., Shima D.T., Calias P., Cunningham E.T. Jr, Guyer D.R., Adamis A.P. Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease // Nat. Rev. Drug Discov. 2006. V. 5. № 2. P. 123−132.
- Gragoudas E.S., Adamis A.P., Cunningham E.T. Jr, Feinsod M., Guyer D.R. Pegaptanib for neovascular age-related macular degeneration // N. Engl. J. Med. 2004. V. 351. № 27. P. 2805−2816.
- Cunha-Vaz J., Faria de Abreu J.R., Campos A.J. Early breakdown of the bloodretinal barrier in diabetes // Br. J. Ophthalmol. 1975. V. 59. № 11. P. 649 656.
- Vinores S.A., Derevjanik N.L., Ozaki H., Okamoto N., Campochiaro P. A. Cellular mechanisms of blood-retinal barrier dysfunction in macular edema // Doc. Ophthalmol. 1999. V. 97. № 3−4. P. 217−228.
- Storkebaum E., Lambrechts D., Carmeliet P. VEGF: once regarded as a specific angiogenic factor, now implicated in neuroprotection // Bioessays. 2004. V. 26. № 9. P. 943−954.
- Csaky K. Anti-vascular endothelial growth factor therapy for neovascular agerelated macular degeneration: promises and pitfalls // Ophthalmology. 2003. V. 110. № 5. P. 879−881.
- Ratner M. Genentech discloses safety concerns over Avastin // Nat. Biotechnol. 2004. V. 22. № 10. P.1198.
- Wahl M.L., Moser T.L., Pizzo S.V. Angiostatin and antiangiogenic therapy in human disease // Rec. Prog. Horm. Res. 2004. V. 59. P. 73−104.
- Preis I., Langer R., Brem H., Folkman J. Inhibition of neovascularization by an extract derived from vitreous // Am. J. Ophthalmol. 1977. V. 84. № 3. P. 323−328.
- Cao Y. Endogenous angiogenesis inhibitors and their therapeutic implications // Int. J. Biochem. Cell. Biol. 2001. V. 33. № 4. P. 357−369.
- Bornstein P. Thrombospondins: structure and regulation of expression // FASEB J. 1992. V. 6. № 14. P. 3290−3299.
- Tucker R.P. The thrombospondin type 1 repeat superfamily // Int. J. Biochem. Cell Biol. 2004. V. 36. № 2. 969−974.
- Kvansakul M., Adams J.C., Hohenester E. Structure of a thrombospondin C-terminal fragment reveals a novel calcium core in the type 3 repeats // Embo. J. 2004. V. 23. № 6. P. 1223−1233.
- Hogg P.J. Thrombospondin 1 as an enzyme inhibitor // Thromb. Haemost. 1994. V. 72. №> 6. P. 787−792.
- Dawson D.W., Pearce S.F., Zhong R., Silverstein R.L., Frazier W.A., Bouck N.P. CD36 mediates the In vitro inhibitory effects of thrombospondin-1 on endothelial cells // J. Cell. Biol. 1997. V. 138. № 3. P. 707−717.
- Jimenez B., Volpert O.V., Crawford S.E., Febbraio M., Silverstein R.L., Bouck N. Signals leading to apoptosis-dependent inhibition of neovascularization by thrombospondin-1 // Nat. Med. 2000. V. 6. № 1. P. 418.
- Simantov R., Febbraio M., Crombie R., Asch A.S., Nachman R.L., Silverstein R.L. Histidine-rich glycoprotein inhibits the antiangiogenic effect of thrombospondin-1 // J. Clin. Invest. 2001. V. 107. № 1. P. 45−52.
- Taraboletti G., Belotti D., Borsotti P., Vergani V., Rusnati M., Presta M., Giavazzi R. The 140-kilodalton antiangiogenic fragment of thrombospondin-1 binds to basic fibroblast growth factor // Cell. Growth. Differ. 1997. V. 8. № 4. P. 471−479.
- Goicoechea S., Orr A.W., Pallero M.A., Eggleton P., Murphy-Ullrich J.E. Thrombospondin mediates focal adhesion disassembly through interactions with cell surface calreticulin // J. Biol. Chem. 2000. V. 275. № 46. P.36 358−36 368.
- Jimenez B., Volpert O.V., Crawford S.E., Febbraio M., Silverstein R.L., Bouck N. Signals leading to apoptosis-dependent inhibition of neovascularization by thrombospondin-1 // Nat. Med. 2000. V. 6. № 1. P. 41−48.
- Rusnati M., Urbinati C., Bonifacio S., Presta M., Taraboletti G. Thrombospondin-1 as a paradigm for the development of antiangiogenic agents endowed with multiple mechanisms of action // Pharmaceuticals. 2010. V. 3. № 4. P. 1241−1278.
- Tolsma S.S., Volpert O.V., Good D.J., Frazier W.A., Polverini P.J., Bouck N. Peptides derived from two separate domains of the matrix protein thrombospondin-1 have anti-angiogenic activity// J. Cell. Biol. 1993. V. 122. № 2. P. 497−511.
- Silverstein R.L. The face of TSR revealed: an extracellular signaling domain is exposed // J. Cell. Biol. 2002. V. 159. № 2. P. 203−206.
- Iruela-Arispe M.L., Luque A., Lee N. Thrombospondin modules and angiogenesis // Int. J. Biochem. Cell. Biol. 2004. V. 36. № 6. P. 1070−1078.
- Tan K., Duquette M., Liu J.H., Dong Y., Zhang R., Joachimiak A., Lawler J., Wang J.H. Crystal structure of the TSP-1 type 1 repeats: a novel layered fold and its biological implication // J. Cell. Biol. 2002. V. 159. № 2. P.373−382.
- Guo N.H., Krutzsch H.C., Inman J.K., Shannon C.S., Roberts D.D. Antiproliferative and antitumor activities of D-reverse peptides derived from the second type-1 repeat of thrombospondin-1 // J. Pept. Res. 1997. V. 50. № 3. P. 210−221.
- Coronella J., Li L., Johnson K., Pirie-Shepherd S., Roxas G., Levin N. Selective activity against proliferating tumor endothelial cells by CVX-22, a thrombospondin-1 mimetic CovXBody // Anticancer Res. 2009. V. 29. № 6. P. 2243−2252.
- Greenaway J., Henkin J., Lawler J., Moorehead R., Petrik J. ABT-510 induces tumor cell apoptosis and inhibits ovarian tumor growth in an orthotopic, syngeneic model of epithelial ovarian cancer // Mol. Cancer Ther. 2009. V. 8. № 1. P. 64−74.
- Becerra S.P., Sagasti A., Spinella P., Notario V. Pigment epitheliumderived factor behaves like a noninhibitory serpin. Neurotrophic activity does not require the serpin reactive loop // J. Biol. Chem. 1995. V. 270. № 43. P. 25 992−25 999.
- Tombran-Tink J., Johnson L.V. Neuronal differentiation of retinoblastoma cells induced by medium conditioned by human RPE cells // Invest. Ophthalmol. Vis. Sci. 1989. V. 30. № 8. P. 1700−1707.
- Cao W., Tombran-Tink J., Chen W., Mrazek D., Elias R., McGinnis J.F. Pigment epithelium-derived factor protects cultured retinal neurons against hydrogen peroxide-induced cell death // J. Neurosci. Res. 1999. V. 57. № 6. P. 789−800.
- DeCoster M.A., Schabelman E., Tombran-Tink J., Bazan N.G. Neuroprotection by pigment epithelial-derived factor against glutamate toxicity in developing primary hippocampal neurons // J. Neurosci. Res. 1999. V. 56. № 6. P. 604−610.
- Houenou L.J., D’Costa A.P., Li L., Turgeon V.L., Enyadike C., Alberdi E., Becerra S.P. Pigment epithelium-derived factor promotes the survival and differentiation of developing spinal motor neurons // J. Comp. Neurol. 1999. V. 412. № 3. P. 506−514.
- Bilak M.M., Corse A.M., Bilak S.R., Lehar M., Tombran-Tink J., Kuncl R.W. Pigment epithelium-derived factor (PEDF) protects motor neurons from chronic glutamate-mediated neurodegeneration // J. Neuropathol. Exp. Neurol. 1999. V. 58. № 7. p. 719−728.
- Barnstable C.J., Tombran-Tink J. Neuroprotective and antiangiogenic actions of PEDF in the eye: Molecular targets and therapeutic potential // Prog. Retin. Eye Res. 2004. V. 23. № 5. P. 561−577.
- Dawson D. W, Volpert O.V., Gillis P., Crawford S.E., Xu H, Benedict W., Bouck N.P. Pigment epithelium-derived factor: A potent inhibitor of angiogenesis // Science. 1999. V. 285. № 5425. P. 245−248.
- Ogata N., Nishikawa M., Nishimura T., Mitsuma Y., Matsumura M. Unbalanced vitreous levels of pigment epithelium-derived factor and vascularendothelial growth factor in diabetic retinopathy // Am. J. Ophthalmol. 2002. V. 134. № 3. P. 348−353.
- Aparicio S., Sawanta S., Lara N., Barnstable C.J. Expression of angiogenesis factors in human umbilical vein endothelial cells and their regulation by PEDF // Biochem. Biophys. Res. Commun. 2005. V. 326. № 2. P. 387−394.
- Cai J., Jiang W.G., Grant M.B., Boulton M. Pigment Epithelium-derived Factor Inhibits Angiogenesis via Regulated Intracellular Proteolysis of Vascular Endothelial Growth Factor Receptor 1 // J. Biol. Chem. 2006. V. 281. № 6. P. 3604−3613.
- Chen L., Zhang S.S., Barnstable C.J., Tombran-Tink J. PEDF induces apoptosis in human endothelial cells by activating p38 MAP kinase dependent cleavage of multiple caspases // Biochem. Biophys. Res. Commun. 2006 V. 348. № 4. P. 1288−1295.
- Zaichuk T.A., Shroff E.H., Emmanuel R., Filleur S., Nelius T., Volpert O.V. Nuclear Factor of Activated T Cells Balances Angiogenesis Activation and Inhibition// J. Exp. Med. 2004. V. 199, № 11. P. 1513−1522.
- Bernard A., Gao-Li J., Franco C.A., Bouceba T., Huet A., Li Z. Laminin Receptor Involvement in the Anti-angiogenic Activity of Pigment Epithelium-derived Factor // J. Biol. Chem. 2009. V. 284. № 16. P. 10 480−10 490.
- Thepparit C., Smith D. R. Serotype-Specific Entry of Dengue Virus into Liver Cells: Identification of the 37-Kilodalton/67-Kilodalton High-Affinity Laminin Receptor as a Dengue Virus Serotype 1 Receptor // J. Virol. 2004. V. 78. № 22. P. 12 647−12 656
- Akache B., Grimm D., Pandey K., Yant S.R., Xu H., Kay M.A. The 37/67-Kilodalton Laminin Receptor Is a Receptor for Adeno-Associated Virus Serotypes 8, 2, 3, and 9 // J. Virol. 2006. V. 80. № 19. P. 9831−9836.
- Nelson J., McFerran N.V., Pivato G., Chambers E., Doherty C., Steele D., Timson D.J. The 67 kDa laminin receptor: structure, function and role in disease // Biosci. Rep. 2008. V. 28. № 1. P. 33−48.
- Alberdi E., Aymerich M.S., Becerra S.P. Binding of pigment epithelium- derived factor (PEDF) to retinoblastoma cells and cerebellar granule neurons: evidence for a PEDF receptor // J. Biol. Chem. 1999. V. 274. № 44. P. 31 605−31 612.
- Li H., Tran V.V., Hu Y., Mark Saltzman W., Barnstable C.J., Tombran-Tink J. A PEDF N-terminal peptide protects the retina from ischemic injury when delivered in PLGA nanospheres // Exp. Eye Res. 2006. V. 83. № 4. P. 824−833.
- Amaral J., Becerra S. P. Effects of Human Recombinant PEDF Protein and PEDFDerived Peptide 34-mer on Choroidal Neovascularization // Invest. Ophthalmol. Vis. Sci. 2010. V. 51. № 3. P. 1318−1326.
- Longeras R., Farjo K., Ihnat M., Ma J.-X. A PEDF-Derived Peptide Inhibits Retinal Neovascularization and BlocksMobilization of Bone Marrow-Derived Endothelial Progenitor Cells // Exp. Diabetes Res. 2012. V. 2012. P. 518 426.
- Gong Q, Yang X, Cai W, Gao G, Yang Z. Expression and purification of functional epitope of pigment epithelium-derived factor in E. coli with inhibiting effect on endothelial cells // Protein J. 2010. V. 29. № 3. P. 167−173.
- Sudhakar A., Boosani C.S. Inhibition of tumor angiogenesis bytumstatin: insights into signaling mechanisms and implications in cancer regression // Pharm. Res. 2008. V. 25. № 12. P. 2731−2739.
- Sundaramoorthy M., Meiyappan M., Todd P., Hudson B.G. Crystal structure of NCI domains. Structural basis for type IV collagen assembly in basement membranes // J. Biol. Chem. 2002. V. 277. № 34. P. 31 142−31 153.
- Hudson B.G., Reeders S.T., Tryggvason K. Type IV collagen: structure, gene organization, and role in human diseases. Molecular basis of Goodpasture and Alport syndromes and diffuse leiomyomatosis // J. Biol. Chem. 1993. V. 268. № 35. P. 26 033−26 036.
- Maeshima Y., Sudhakar A., Lively J.C., Ueki K., Kharbanda S., Kahn C.R., Sonenberg N., Hynes R.O., Kalluri R. Tumstatin, an endothelial cell-specific inhibitor of protein synthesis // Science. 2002. V. 295. № 5552. P. 140−143.
- Han J., Ohno N., Pasco S., Monboisse J.C., Borel J.P., Kefalides N.A. A cell binding domain from the alpha3 chain of type IV collagen inhibits proliferation of melanoma cells // J. Biol. Chem. 1997. V. 272. № 33. P. 2 039 520 401.
- Boosani C.S., Mannam A.P., Cosgrove D., Silva R., Hodivala-Dilke K.M., Keshamouni V.G., Sudhakar A. Regulation of COX-2 mediated signaling by {alpha} 3 type IV noncollagenous domain in tumor angiogenesis // Blood. 2007. V. 110. № 4. P. l 168−1177.
- Church R.D., Fleshman J.W., McLeod H.L. Cyclo-oxygenase 2 inhibition in colorectal cancer therapy // Br. J. Surg. 2003. V. 90. № 9. P. 10 551 067.
- Zeisberg M., Khurana M., Rao V.H., Cosgrove D., Rougier J.P., Werner M.C., Shield C.F. 3rd, Werb Z,. Kalluri R. Stage-specific action of matrix metalloproteinases influences progressive hereditary kidney disease // PLoS Med. 2006. V. 3.№ 4. P. el00.
- Gunda V., Wang S., Sheibani N., Sudhakar, A. Inhibitory Effect of Tumstatin on Corneal Neovascularization Both In-vitro and In-vivo // J. Clinic. Experiment. Ophthalmol. 2011. V.2. P. 132.
- Dhanabal M., Ramchandran R., Volk R., Stillman I. E., Lombardo M., Iruela-Arispe M. L., Simons M., Sukhatme V.P. Endostatin: yeast production, mutants, and antitumor effect in renal cell carcinoma // Cancer Res. 1999. V. 59. № l.P. 189−197.
- O’Reilly M.S., Boehm T., Shing Y., Fukai N., Vasios G., Lane W.S., Flynn E., Birkhead J.R., Olsen B.R., Folkman, J. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth // Cell. 1997. V. 88. № 2. P. 277−285.
- Boehm T., Folkman J., Browder T., O’Reilly M.S. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance // Nature. 1997. V. 390. № 6658. P. 404−407.
- Abdollahi A., Hahnfeldt P., Maercker C., Grone H.J., Debus J., Ansorge W., Folkman J., Hlatky L., Huber P.E. Endostatin’s antiangiogenic signaling network // Mol. Cell. 2004. V. 13. № 5. P. 649−663.
- Hohenester E., Sasaki T., Olsen B.R., Timpl R. Crystal structure of the angiogenesis inhibitor endostatin at 1.5 A resolution // EMBO J. 1998. V. 17. № 6. P. 1656−1664.
- Han Q., Fu Y., Zhou H., He Y., Luo Y. Contributions of Zn (II)-binding to the structural stability of endostatin // FEBS Lett. 2007. V. 581. № 16. P. 30 273 032.
- Fu Y., Tang H., Huang Y., Song N., Luo Y. Unraveling the mysteries of endostatin // IUBMB Life. 2009. V. 61. № 6. P. 613−626.
- Shi H., Huang Y., Zhou H., Song X., Yuan S., Fu Y., Luo Y. Nucleolin is a receptor that mediates antiangiogenic and antitumor activity of endostatin // Blood. 2007. V. 110. № 8. P. 2899−2906.
- Javaherian K., Park S.Y., Pickl W.F., LaMontagne K.R., Sjin R.T., Gillies S., Lo K.M. Laminin modulates morphogenic properties of the collagen XVIII endostatin domain // J. Biol. Chem. 2002. V. 277. № 47. P. 45 211—45 218.
- Lee S.J., Jang J.W., Kim Y.M., Lee H.I., Jeon J.Y., Kwon Y.G., Lee
- T. Endostatin binds to the catalytic domain of matrix metalloproteinase-2 // FEBS Lett. 2002. V. 519. № 1−3. P. 147−152.
- Ginisty H., Sicard H., Roger B., Bouvet P. Structure and functions of nucleolin // J. Cell Sci. 1999. V. 112, № 6. P. 761−772.
- Erard M.S., Belenguer P., Caizergues-Ferrer M., Pantaloni A., Amalric, F. A major nucleolar protein, nucleolin, induces chromatin decondensation by binding to histone HI // Eur. J. Biochem. 1988. V. 175. № 3. p. 525−530.
- Kharrat A., Derancourt J., Doree M., Amalric F., Erard M. Synergistic effect of histone HI and nucleolin on chromatin condensation in mitosis: role of a phosphorylated heteromer. Biochemistry. 1991.V. 30. № 42. P. 10 329−10 336.
- Christian S., Pilch J., Akerman M.E., Porkka K., Laakkonen P., Ruoslahti E. Nucleolin expressed at the cell surface is a marker of endothelial cells in angiogenic blood vessels // J. Cell Biol. 2003. V. 163. № 4. P. 871−878.
- Huang Y., Shi H., Zhou H., Song X., Yuan S., Luo Y. The angiogenic function of nucleolin is mediated by vascular endothelial growth factor and nonmuscle myosin // Blood. 2006. V. 107. № 9. P. 3564−3571.
- Cattaneo M.G., Pola S., Francescato P., Chillemi F., Vicentini L.M., Human endostatin-derived synthetic peptides possess potent antiangiogenic properties in vitro and in vivo // Exp. Cell Res. 2003. V. 283. № 2. P. 230−236.
- Morbidelli L., Donnini S., Chillemi F., Giachetti A., Ziche M., Angiosuppressive and angiostimulatory effects exerted by synthetic partial sequences of endostatin // Clin. Cancer Res. 2003. V. 9. № 14. P. 5358−5369.
- Wickstrom S.A., Alitalo K., Keski-Oja J. An endostatinderived peptide interacts with integrins and regulates actin cytoskeleton and migration of endothelial cells // J. Biol. Chem. 2004.V. 279. № 19. P. 20 178−20 185.
- Pieraccini S., Sironi M., Francescato P., Speranza G., Vicentini L.M., Manitto P. A molecular dynamics study of human endostatin and its synthetic fragments with antiangiogenic properties // Phys. Chem. Chem. Phys. 2006. V. 8. № 26. P. 3066−3071.
- Walter-Yohrling J., Morgenbesser S., Rouleau C., Bagley R., Callahan M., Weber W., Teicher B.A. Murine endothelial cell lines as models of tumor endothelial cells // Clin. Cancer Res. 2004. V. 10. № 6. P. 2179−2189.
- Laemmli U.K. Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4 // Nature. 1970. V. 227. № 5259. P. 680−685.
- Lowry O.H., Rosebrough N.J., Farr A.L., Randall R.J. Protein measurement with the Folin phenol reagent // J. Biol. Chem. 1951. V. 193. № 1. P. 265−275.
- Hamano Y., Kalluri R. Tumstatin, the NCI domain of alpha3 chain of type IV collagen, is an endogenous inhibitor of pathological angiogenesis and suppresses tumor growth // Biochem. Biophys. Res. Commun. 2005. V. 333. № 2. P. 292−298.
- Maeshima Y., Colorado P.C., Kalluri R. Two RGD-independent alphavbeta3 integrin binding sites on tumstatin regulate distinct antitumor properties // J. Biol. Chem. 2000. V. 275. № 31. P. 23 745−23 750.
- Maeshima Y., Colorado P.C., Torre A. Distinct antitumor properties of a type IV collagen domain derived from basement membrane // Biol. Chem. 2000. V. 275. № 28. P. 21 340−21 348.
- Walker J.R., Altman R.K., Warren J. W, Altman E. Using protein-based motifs to stabilize peptides // J. Peptide. Res. 2003. V. 62. P. 214−226.
- Esipov R.S., Stepanenko V.N., Beyrakhova K.A., Muravjeva T.I., Miroshnikov A.I. Production of thymosin alpha 1 via non-enzymatic acetylation of the recombinant precursor // Biotechnol. Appl. Biochem. 2010. V. 56. № 1. P. 1725.
- Tombran-Tink J., Chader G.G., Johnson L.V. PEDF: a pigment epithelium-derived factor with potent neuronal differentiative activity // Exp. Eye Res. 1991. V. 53. № 3. P. 411−414.
- Filleur S., Nelius T., de Riese W., Kennedy R.C. Characterization of PEDF: a multi-functional serpin family protein // J. Cell. Biochem. 2009. V. 106. № 5. P. 769−775.
- Dawson D.W., Volpert O.V., Gillis P., Crawford S.E., Xu H., Benedict W., Bouck N.P. Pigment epithelium-derived factor: a potent inhibitor of angiogenesis // Science. 1999. V. 285. № 5425. P. 245−248.
- Fong B.A., Wu W.Y., Wood D.W. The potential role of self-cleaving purification tags in commercial-scale processes //Trends Biotechnol. 2010 V. 28. № 5. P. 272−279.
- Arnau J., Lauritzen C., Petersen G.E., Pedersen J. Current strategies for the use of affinity tags and tag removal for the purification of recombinant proteins // Protein Expr. Purif. 2006, V. 48. № 1. P. 1−13.
- Esipov R.S., Stepanenko V.N., Gurevich A.I., Chupova L.A., Miroshnikov A.I. Production and purification of recombinant human glucagon overexpressed as intein fusion protein in Escherichia coli // Protein Pept. Lett. 2006. V. 13. № 4. P. 343−347.
- Esipov R.S., Stepanenko V.N., Chupova L.A., Boyarskikh U.A., Filipenko M.L., Miroshnikov A.I. Production of recombinant human epidermal growth factor using Ssp dnaB mini-intein system // Protein Expr. Purif. 2008. V. 61. № l.P. 1−6.
- Stepannenko V.N., Esipov R.S., Gurevich A.I., Chupova L.A., Miroshnikov A.I. Recombinant oxyntomodulin// Bioorg. Khim. 2007. V. 33. № 2. P. 245−250.
- Мирошников А.И., Лихванцева В. Г., Степанова Е. В., Арутюнян Е. В., Осипов Р. А., Бейрахова К. А., Степаненко В. Н., Белоус О. В. // Офтальмохирургия. 2011. № 1. С. 76−82.
- O’Connel К., Edidin М. A mouse lymphoid endothelial cell line immortalized by simian virus 40 binds lymphocytes and retains functional characteristics of normal endothelial cells // J. Immunol. 1990. V. 144. № 2. P. 521−525.
- Apte R.S., Barreiro R.A., Duh E., Volpert O., Ferguson T.A. Stimulation of neovascularization by the anti-angiogenic factor PEDF // Invest. Ophthalmol. Vis. Sci. 2004. V. 45. № 12. P. 4491^1497.
- Montezuma S.R., Vawas D., Miller J.W. Review of the ocular angiogenesis animal models // Semin. Ophthalmol. 2009. V. 24. № 2. P. 52−61.
- Gunda V., Wang S., Sheibani N., Sudhakar, A. Inhibitory Effect of Tumstatin on Corneal Neovascularization Both In-vitro and In-vivo // J. Clinic. Experiment. Ophthalmol. 2011. V.2. P. 132.
- Rosenfeld P.J., Brown D.M., Heier J.S., Boyer D.S., Kaiser P.K., Chung C.Y., Kim R.Y., MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration // N. Engl. J. Med. 2006. V. 355. № 14. P. 14 191 431.
- Schaal S., Kaplan H., Tezel T. Is there tachyphylaxis to intravitreal anti-vascular endothelial growth factor pharmacotherapy in age-related macular degeneration? // Ophthalmology. 2008. V. 115. № 12. P. 2199−2205.
- Bradley J., Ju M., Robinson G.S. Combination therapy for the treatment of ocular neovascularization // Angiogenesis. 2007. V. 10. № 2. P. 141−148.
- Brar V.S., Sharma R.K., Murthy R.K., Chalam K.V. Bevacizumab neutralizes the protective effect of vascular endothelial growth factor on retinal ganglion cells // Mol Vis. 2010. V. 16. P. 1848−1853.1. Благодарности